Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial
| dc.contributor.author | Bliss, J | |
| dc.contributor.author | Porta, N | |
| dc.contributor.author | Banerji, J | |
| dc.contributor.author | Larkin, J | |
| dc.date.accessioned | 2024-03-01T11:22:14Z | |
| dc.date.available | 2024-03-01T11:22:14Z | |
| dc.identifier.citation | Cell Reports Medicine, | en_US |
| dc.identifier.issn | 2666-3791 | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/6168 | |
| dc.identifier.eissn | 2666-3791 | |
| dc.identifier.eissn | 2666-3791 | |
| dc.language.iso | eng | en_US |
| dc.publisher | Elsevier | en_US |
| dc.relation.ispartof | Cell Reports Medicine | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
| dc.title | Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial | en_US |
| dc.type | Journal Article | |
| dcterms.dateAccepted | 2024-01-26 | |
| dc.date.updated | 2024-02-08T11:52:04Z | |
| rioxxterms.version | AM | en_US |
| rioxxterms.type | Journal Article/Review | en_US |
| pubs.organisational-group | ICR | |
| pubs.organisational-group | ICR/Primary Group | |
| pubs.organisational-group | ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies | |
| pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
| pubs.publication-status | Accepted | |
| icr.researchteam | Clin Trials & Stats Unit | en_US |
| dc.contributor.icrauthor | Bliss, Judith | |
| dc.contributor.icrauthor | Porta, Nuria | |
| icr.provenance | Deposited by Ms Jessica Perry (impersonating Prof Judith Bliss) on 2024-02-08. Deposit type is initial. No. of files: 1. Files: NICAM CR-MEDICINE-D-23-01778_accepted version.pdf |
Files in this item
This item appears in the following collection(s)
Except where otherwise noted, this item's license is described
as
http://creativecommons.org/licenses/by/4.0/